News and Events

News

All categories

Earnings

Press Release

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

May 23, 2023

Affimed Announces Annual General Meeting of Shareholders

May 22, 2023

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

May 16, 2023

Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

May 11, 2023

Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)

April 26, 2023

Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting

April 17, 2023

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

April 16, 2023

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

April 6, 2023

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

March 29, 2023

Affimed Reports 2022 Financial Results and Operational Progress

March 23, 2023

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

Affimed Announces Annual General Meeting of Shareholders

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

Affimed Reports 2022 Financial Results and Operational Progress

Events